Movers and SHAKERS
PDS Biotechnology Corp (PDSB)
Phase 2 Interim Analysis in HPV Shows Strong Response Rate
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
PDS Biotech presented the first analysis from the Phase 2 trial testing PDS0101 in HPV16+ (human papilloma virus 16 positive) cancers. The data presentation was from the first 25 patients out of the target enrollment of 56 patients. The trial enrolls patients who have failed first-line treatments but were naïve to checkpoint inhibitors as well as those who had become refractory to checkpoint inhibitor treatment.
PDS0101 is a triple combination therapy containing Versimue, the bifunctional checkpoint inhibitor bintrafusp, and Il-12 as an immune cytokine. This combination is intended to allow the immune system to recognize the tumor cell, then activate both CD4+ helper and CD8+ killer T-cells for a potent and durable immune response. Survival for patients who tested HPV16+ was 89% compared with 57% for ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.